A Phase 2 Clinical Trial to Evaluate Zanubrutinib Combined With BR (Bendamustine/Rituximab) Regimen in Subjects With Newly-diagnosed Waldenström's Macroglobulinemia

Clinical trial NCT05979948 · UNKNOWN

Trial details

NCT number: NCT05979948
Sponsor: Shanghai Changzheng Hospital
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Waldenström's Macroglobulinemia

Start date: 2023-08-01
Primary completion: 2025-04-01
Enrollment: 60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.